Fengyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for the concentrated solution of tirofiban hydrochloride for injection, approved and issued by the State Drug Administration. The certificate number is 2026S03986, and the drug approval number is Sinopharm standard H20266454. The approval number is valid until November 2, 2031. This drug is a class of 4 chemicals, 50 ml: 12.5 mg. It is used to prevent early myocardial infarction in adult patients with non-ST segment elevation acute coronary syndrome, and to reduce the occurrence of major cardiovascular events in patients with acute myocardial infarction planning direct PCI. Obtaining this registration certificate will enrich the company's product line and optimize the product structure.

Fengyuan Pharmaceutical announced that the company recently received the “Drug Registration Certificate” for the concentrated solution of tirofiban hydrochloride for injection, approved and issued by the State Drug Administration. The certificate number is 2026S03986, and the drug approval number is Sinopharm standard H20266454. The approval number is valid until November 2, 2031. This drug is a class of 4 chemicals, 50 ml: 12.5 mg. It is used to prevent early myocardial infarction in adult patients with non-ST segment elevation acute coronary syndrome, and to reduce the occurrence of major cardiovascular events in patients with acute myocardial infarction planning direct PCI. Obtaining this registration certificate will enrich the company's product line and optimize the product structure.